Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19 [PDF]
Frontiers in Immunology, 2023 Patients with coronavirus disease-2019 (COVID-19) have an increased risk of thrombosis and acute respiratory distress syndrome (ARDS). Thrombosis is often attributed to increases in plasminogen activator inhibitor-1 (PAI-1) and a shut-down of ...
Tetiana Yatsenko +12 more
doaj +2 more sources
Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice [PDF]
Scientific Reports, 2023 Although several angiogenesis-related factors are reportedly involved in the pathogenesis of ulcerative colitis (UC), the mechanisms by which they contribute to disease are unclear.
Yoshifumi Kida +13 more
doaj +2 more sources
The structure of the urokinase-type plasminogen activator receptor gene [PDF]
Blood, 1994 The cellular receptor for urokinase-type plasminogen activator (uPAR) is a glycosylphosphatidylinositol (GPI)-anchored membrane protein that plays a central role in pericellular plasminogen activation. It contains 313 amino acid residues, including 28 cysteine residues in a pattern of three homologous repeats. The cysteine residue pattern suggests that
JR Casey +4 more
+7 more sources
Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer [PDF]
Journal of Translational Medicine, 2022 Urokinase-type plasminogen activator receptor (uPAR) is an attractive target for the treatment of cancer, because it is expressed at low levels in healthy tissues but at high levels in malignant tumours.
Bing-Tao Zhai +8 more
doaj +2 more sources
Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator [PDF]
BiomedicinesThe urokinase-type plasminogen activator receptor (uPAR) is a unique protease binding receptor, now recognized as a key regulator of inflammation.
Mostafa Hamada +9 more
doaj +2 more sources
Corrigendum: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19 [PDF]
Frontiers in ImmunologyTetiana Yatsenko +12 more
doaj +2 more sources
Medical Journal of Babylon, 2023 Background: Type 2 diabetes mellitus is a progressive and chronic disease manifested by β-cell dysfunction and improved insulin resistance. Higher levels of urokinase-type plasminogen activator receptors have been found to predict morbidity and mortality
Melak Saleh Mohammed, Hind Shakir Ahmed
doaj +1 more source
Animal Models and Experimental Medicine, Volume 5, Issue 6, Page 542-549, December 2022., 2022 Schematic diagram showing RHAU can bind and unwind the G4 “knots” to modulate embryonic development and post‐natal organ function. Deficiency of RHAU gives rise to embryonic lethality, impaired organogenesis and organ dysfunction. RHAU modulates Nkx2‐5 mRNA and Yap1 mRNA at the post‐transcriptional level and facilitates the transcription of c‐Kit and ...
Chensi Yang +5 more
wiley +1 more source
The uPA System Differentially Alters Fibroblast Fate and Profibrotic Ability in Skin Fibrosis
Frontiers in Immunology, 2022 Skin fibrosis is a common pathological feature of various diseases, and few treatment strategies are available because of the molecular pathogenesis is poorly understood.
Ming-Li Zou +15 more
doaj +1 more source
Urokinase‐Type Plasminogen Activator, an Endogenous Antibiotic [PDF]
The Journal of Infectious Diseases, 2005 Urokinase-type plasminogen activator (uPA) is a serine protease that not only displays fibrinolytic function but also modulates innate and adaptive immune responses. In the present study, we assessed whether uPA acts as an endogenous antibiotic. It has been demonstrated that uPA inhibits growth of Staphylococcus aureus both in vivo and in vitro ...
Tao Jin +2 more
openaire +2 more sources